Genomic Health, Inc.
) recently announced the presentation of results from multiple
Oncotype DX breast cancer studies at the 9
European Breast Cancer Conference (EBCC-9), scheduled from March
19 to 21 in Glasgow, Scotland, U.K.
The data to be presented is expected to draw attention toward
the need for greater availability of a standard predictive
genomic testing, like Oncotype DX, to promote more informed
chemotherapy treatment decisions in early-stage breast cancer
patients in Europe.
The Oncotype DX breast cancer test is the only multigene
expression test that is commercially available. It is also
supported by clinical evidence that validates its ability to
predict the likelihood of chemotherapy benefits as well as
recurrence in early-stage breast cancer. The Oncotype DX gene
expression assay is designed for women with early-stage (stage I
or II), node-negative, estrogen receptor-positive (ER+) invasive
breast cancer prescribed to be treated with therapy.
After a thorough research on Oncotype DX breast cancer test,
comprising almost 16 studies conducted with 1,766 patients, it
can be concluded that Oncotype DX has successfully demonstrated
its clinical utility and cost effectiveness.
Genomic Health has earlier presented results from multiple
studies propagating the benefits of Oncotype DX test in
conferences like the 2014 American Society of Clinical Oncology
Gastrointestinal Cancer (ASCO GI) Symposium and the 36
Annual CTRC-AACR San Antonio Breast Cancer Symposium.
Owing to increased popularity of the Oncotype DX test among
physicians, Genomic Health experienced a 15% rise in the test
volume to more than 85,000 tests in 2013. Management also
estimates the adoptability of the tests to further increase to
98,000-102,500 tests in 2014.
Currently, Genomic Health carries a Zacks Rank #4 (Sell). Some
better-ranked stocks in the broader healthcare sector worth
Alexion Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc.
). All these stocks sport a Zacks Rank #1 (Strong Buy).
ALKERMES INC (ALKS): Free Stock Analysis
ALEXION PHARMA (ALXN): Free Stock Analysis
ANI PHARMACEUT (ANIP): Free Stock Analysis
GENOMIC HEALTH (GHDX): Free Stock Analysis
To read this article on Zacks.com click here.